Loading…
Lean Rx, Inc. dba SkinnyRx was cited for marketing compounded semaglutide and tirzepatide drug products with false or misleading claims in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs on product labels and made deceptive claims that the compounded products contained "the same active ingredient as FDA-approved medications" and were equivalent to brand-name GLP-1 treatments like Mounjaro® and Zepbound®, when compounded drugs are not FDA-approved. These violations rendered the products misbranded under sections 502(a) and 502(bb) of the FDCA, and the company introduced these products into interstate commerce through its website at skinnyrx.com.